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Abstract
This review deals with the methods of identifying genes that have been activated by inner or outer
impulses. The activation and subsequent expression of a gene can be detected by its transcription
into a corresponding messenger ribonucleic acid (mRNA). Principles of the methods for
identification of individual activated genes, as well as groups of activated genes are described, the
former methods being mostly based on subtractive hybridization and serial analysis of gene
expression (SAGE), the latter on microarrays. Examples of gene activation by the hormone 17beta-
estradiol (E2) are given.
Introduction
In previous reviews, methods for the measurement of
receptors and their interactions with other transcription
factors and genes were described [1-3]. In this review, gene
activation is discussed with a particular emphasis on the
methods enabling detection of the activated, turned-on,
genes. The action of the hormone 17beta-estradiol (E2) is
taken as an example of the function of many other small-
molecule compounds in gene activation and in the
expression of the activated gene.
The life of humans and animals is influenced by the activ-
ity of a series of genes that are kept in a silent state, or are
activated, depending on the temporary needs of the body.
This switching on and off of each gene is executed by an
assembly of transcription factors forming a transcription
initiation complex (TIC).
Examples of such transcription factors are estrogen recep-
tors (ER-alpha, ER-beta, and possibly other isomers) that,
before being incorporated into a TIC, have to be activated
by E2. This hormone itself is synthesized, when an initial
signal is given, by virtue of an activation of a series of
appropriate genes. Via ER, E2 has manifold biological
effects. Biological targets of E2 are, inter alia, blood vessel
walls [4-8], blood platelets [9], bone [7,10-12], breast
cancer cells [13], central nervous system [7,14,15], retinal
pigment epithelium [16], synthesis of clotting factors
[17].
It is evident that E2 is associated with many biological
effects and that many genes must be involved. Conse-
quently, ER must be able to bind to DNA segments, called
response elements, in the neighborhood of various genes.
The response elements participate, together with other
transcription factors, in the formation of TICs that are spe-
cific for each gene.
An important problem, currently studied in many labora-
tories, is to find out which genes are activated in various
circumstances. The methods that solve this problem are
based on a comparative (differential) approach. A test
(target) sample, containing active genes is compared with
a control sample in which the genes have not been
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activated. Using this approach, the active genes are singled
out among the multitude of inactive genes. However, the
comparisons may reveal the opposite of activation, i.e.,
downregulation of genes.
Generally, the activity of a gene is characterized by its tran-
scription into mRNAs as the first step leading to the syn-
thesis of specific proteins. Non-activated genes in the
control tissue do not produce any corresponding mRNAs.
In most methods, the mRNAs prepared from the test and
control tissue are each reverse transcribed into the corre-
sponding complementary deoxyribonucleic acid (cDNA),
in order to enable a substantial increase of the material for
analysis by polymerase chain reaction (PCR) [2]. As most
methods do not operate with full mRNA transcripts, but
with shorter sequences, the allocation of such sequences
to known (or unknown) genes has to be found by
advanced computer programs and gene databases.
The methods used for the identification of active genes are
sketched below. Included are even methods that have not
yet been used for the identification of E2-activated genes.
It has to be mentioned that only principles, not technical
details are dealt with in this review. Neither the tech-
niques of cloning or of identification of genes by sequenc-
ing are described here. The readers who are not familiar
with these techniques are advised to consult appropriate
textbooks [e.g., [18]]. The dedicated computer programs
and databases that are needed for the identification of
sequences or genes will not be described here either. These
can be found in the references quoted below. It will only
be mentioned here that the large databases are GenBank
http://www.ncbi.nlm.nih.gov and Celera http://www.cel
eradiscoverysystem.com.
Activated (expressed) genes can be found by comparison
of gene contents in the test and control tissues. There are
essentially two approaches for finding activated genes: (i)
an individual identification, or (ii) an identification of
expression profiles after hybridization to a set of known
gene fragments (probes) attached to chips in microarrays.
Individual identification
This approach means that genes are identified individu-
ally, even if several genes can eventually be picked up after
cloning. There are several methods that can be used.
Differential display
Differential display seems to be the technically simplest
method. Its name stems from the end-point that is a com-
parison of a side-by-side display of the test and control
preparations by electrophoresis. In its basic form, total
RNA of the test and control samples is separately sub-
jected to reverse transcription into cDNA that, in turn, is
PCR-amplified using arbitrarily chosen primers. The prod-
ucts are applied to a gel electrophoresis and the band(s)
that are specific for one of the preparations are cut from
the gel, further amplified by PCR (using the same primers)
and eventually sequenced [19].
In a more advanced version, mRNAs of the test and con-
trol cells are separately reverse transcribed to cDNA (Fig.
1). Each transcription is carried out in the presence of a
oligo(dT) primers, directed to the poly(A) tail at the 3' ter-
minus of the mRNA and constructed as 5'(NMT11)3'
where N can be guanine (G), adenine (A), thymine (T), or
cytosine (C), and M is G, A, or C [20-22]. The primers with
G residues are superior to those having one C residue.
Those ending in A or T are the least efficient. With use of
an arbitrary decamer as the second primer, a PCR is car-
ried out to amplify the transcript in order to obtain a suf-
ficient working material. This is usually done in the
presence of a radioactive nucleotide. Other methods are
commonly used, such as silver staining. Amplified DNA
fragments are separated on a denaturing polyacrylamide
gel, the test preparation side by side with the control. Each
band differing from those seen in the control electro-
phoresis is then used for sequencing, subcloning, or as a
probe for cDNA library screening. Large amount of results
can be obtained depending on the variation in N and M
nucleotides. In spite of the basic simplicity of the proce-
dure, the time and workload can be considerable, depend-
ing on the number of NM combinations tried.
Subtractive hybridization with hydroxylapatite separation
The test mRNA is reverse transcribed into cDNA [23]. This
is hybridized with the mRNA of the control sample (Fig.
2). A portion of the test cDNA (corresponding to the acti-
vated gene) does not find any complementary part in the
mRNA of the control sample and remains non-hybridized
as a single-stranded cDNA (ss-cDNA). This can be isolated
by chromatography on a hydroxylapatite column. The
hybridization of the isolated ss-cDNA with control mRNA
followed by another chromatography can be repeated to
increase the purity of the isolated product [23]. A cDNA
library is produced and the subtracted sequence eventu-
ally identified. Alternatively, a second hybridization of the
isolated ss-cDNA is carried out with the original test
mRNA giving rise to a cDNA-mRNA hybrid which, after
conversion to double stranded cDNA, is inserted into a
vector, a cDNA library is constructed and several specific
cDNA clones are isolated, leading to the identification of
several genes [24].
In another variant [25], the test and control mRNAs are
both reverse transcribed into cDNA. cDNA of the test sam-
ple is hybridized with cDNA of the control sample. The
non-hybridized part of the test cDNA is a single-stranded
DNA that is separated by hydroxylapatite. The single-
stranded DNA is cloned into a vector to produce aReproductive Biology and Endocrinology 2004, 2:68 http://www.rbej.com/content/2/1/68
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subtracted library. Clones with a strong hybridization sig-
nal to the subtracted probe are selected and sequenced.
Subtractive suppression hybridization with PCR
Isolation of a single-stranded test cDNA is not needed in
this method. mRNAs of the test and control samples are
prepared and each is reverse transcribed into cDNA. Each
transcript is digested with the enzyme RsaI to obtain
shorter, blunt-ended fragments. The test cDNA is divided
into two portions (see Fig. 3). One of them is ligated with
Adapter A, the second with adapter B. Each portion is
hybridized with an excess of control cDNA. A mixture of
hybridization products is formed (Fig. 3). A tiny fraction
of cDNA remains unhybridized, single-stranded. This is a
fragment that may be called specific, or differentially
expressed, or subtracted. It originates from the gene that
had been activated. It is absent in the control sample. This
specific fragment is bound either to Adapter A or B in the
two portions. In the second hybridization, the portions
are mixed. After annealing, a small amount of the specific
fragment is obtained double-stranded. It contains Adapter
A on the one end and Adapter B on the other. After adding
primers specific for the Adapters, the ends are filled and
the specific fragment is amplified by PCR to make sure
that sufficient amounts are available for a further process-
ing. Cloning, sequencing and comparing with a gene data-
base establish the identity of the gene(s) [26,27] [http://
www.clontech.com – "PCR-Select Subtraction kit"]. In
Principle of a differential display Figure 1
Principle of a differential display. Test and control mRNA are separately reverse transcribed in the presence of anchored 
oligo(dT) primers containing nucleotides N and M in various combinations (see the text). The same primer and an arbitrary 
decamer are then used as primers in a PCR. The products are subjected to electrophoresis (PAGE). An additional band (see 
arrow) in the test sample represents a gene that had not been activated in the control sample. A11 and T11 denote eleven A 
and T molecules, respectively.
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NM(T11)
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contrast to the above methods, the primers for PCR ampli-
fication are clearly defined, avoiding thus problems with
random primers. This method was used in a number of
studies, such as the identification of genes upregulated in
rats by E2 and progesterone treatment [28]. A predecessor
of this technique is the "representational difference anal-
ysis" [29,30].
Expressed sequence tags (EST)
To describe the EST method, the following example is
given. cDNA libraries were prepared by reverse transcrip-
tion from mRNAs of the tissues to be examined [31]. The
libraries were converted to plasmids, transfected into
Escherichia coli and plated. Hundreds of clones were
picked at random. These were subjected to sequencing,
Flow-sheet of subtractive hybridisation with hydroxylapatite separation Figure 2
Flow-sheet of subtractive hybridisation with hydroxylapatite separation. Test mRNA is reverse transcribed into a cDNA. This 
is hybridized with control mRNA. The non-hybridized portion of the single-stranded sequence of test cDNA is separated by 
chromatography on hydroxylapatite (HAP) and further processed.
Test
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followed by computer matching to known genes listed in
the GenBank database. The average length of a sequence
was 397 bases; ESTs longer than 150 bases were found to
be most useful for similarity searches and mapping.
Subtractive hybridization (see above) was used to isolate
the ESTs specific for one of the libraries. For example, a
fibroblast cell line cDNA library was hybridized with a
hippocampus library; the common sequences were
removed and the specific hippocampus sequences
remained. Using the EST method, more than 2000 human
brain genes were identified [32].
Serial Analysis of Gene Expression (SAGE)
The SAGE allows serial analysis of gene expression, an
analysis of thousands of transcripts. It is based on the
Outline of subtractive suppression hybridisation with PCR Figure 3
Outline of subtractive suppression hybridisation with PCR. Test cDNA and control cDNA are digested with RsaI. The test 
cDNA sequences are divided into two halves, one of them being ligated with Adapter A (empty squares), the second one with 
Adapter B (filled squares). Each half is hybridized with control cDNA. The single-stranded (non-hybridized) sequences of both 
halves (denoted by asterisks) are annealed in a second hybridization step, primers to the Adapters are added and, after PCR, 
cloning and gene identification are carried out.
Test Control
cDNA cDNA
RsaI digestion RsaI digestion
Ligation with 
Adapter A
Ligation with 
Adapter B
Hybridizations with control cDNA
Test
cDNA
RsaI digestion
Pooling, second hybridization
Filling ends
(among other products)
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assumption that a short nucleotide sequence 10 base pairs
(bp) – a tag – contains sufficient information to uniquely
identify a transcript. In this respect SAGE differs from the
EST approach.
The principle of SAGE is as follows: mRNA is reverse tran-
scribed into cDNA with use of a biotinylated primer, the
cDNA is cleaved with a restriction endonuclease and the
3' portions are then isolated by binding to streptavidin
beads [33]. In another version(http://www.invitro
gen.com) (Fig. 4), mRNAs are captured prior to reverse
transcription on oligo(dT) magnetic beads. Double
stranded cDNAs are synthesized and digested with the
restriction endonuclease NlaIII that cleaves most tran-
scripts at least once. The part attached to the magnetic
bead is further processed. The reaction mixture is divided
into two portions. The portions are ligated via a restriction
site R to an adapter A and B, respectively, each consisting
of 40 bp. Taking advantage of the restriction sites R, both
portions are cleaved with the restriction enzyme BsmFI in
the distance of 14 bp. In this way "tags" are formed. Out
of these 14 bp, 4 bp are a non-specific segment GTAC.
These tags are blunt-ended with the Klenow fragment of
DNA polymerase I. The two separate pools of tags are
ligated together via a blunt-end ligation to produce "dit-
ags". The ditags, flanked by the adapters A and B, are
amplified by PCR with use of primers for A and B. The
adapters are removed by the enzyme NlaIII and the ditags
are concatenated. The resulting concatemers (a series of
linked ditags) are cloned into a plasmid vector to create a
SAGE library. Individual clones are then sequenced. SAGE
is carried out for each sample to be compared.
Thanks to the concatenation, many tags can be detected in
a single clone [33]. As each tag is supposed to uniquely
identify a transcript, SAGE can generate a comprehensive
profile of gene expression. Indeed, many unique tran-
scripts were identified with use of SAGE tags [34]. The
method is particularly useful for detecting genes of low
level of expression or in rare tissues (e.g., early embryo)
[35,36]. In addition, the amount of individual tags pro-
vides quantitative estimates of gene expression [37].
Still, the specificity of detection of genes with use of the
short tags is not absolute. There are two main problems
[38]. The first one is that many SAGE tags have no match
to known sequences in databases. These tags may repre-
sent so far unidentified genes, but their shortness makes it
difficult to characterize the genes. The second problem is
that the SAGE tags may find multiple matches in the data-
bases [39,40]. Therefore, attempts have been made to
increase the specificity by prolongation of the tags by var-
ious methods.
One such method is called GLGI (Generation of Longer
cDNA fragments from SAGE tags for Gene Identification)
[34,38,40]. The main feature of this method is the use of
a SAGE tag as the sense primer for the PCR of a segment
of cDNA. An anchored oligo(dT) serves as an antisense
primer. In this manner a cDNA "tag" of up to several hun-
dred bases is created. However, this method does not
seem to improve the specificity of SAGE because even
"non-specific" tags are co-amplified.
Better of seems to be another variant of SAGE, the Long-
SAGE [41]. This is based on the use of tags 21 bp (out of
which 4 represent a restriction site), tags longer than those
in SAGE. The prolongation of tags is achieved by the use
of the restriction endonuclease MmeI. The longer tags
increase the power of identification of genes, while not
diminishing the sensitivity of SAGE given by the use of
PCR and concatenation. Theoretical calculations showed
that >99.8% of the 21 bp tags were expected to occur only
once in a genome.
SAGE was used for the investigation of differences in gene
expression in various health conditions. In the studies of
breast tumors [37], global gene expression profiles in
breast carcinoma cells were compared with those in nor-
mal mammary epithelial cells. The patterns of gene clus-
ters in normal tissue were distinctly different from those
of tumors of different stage and histological grade. The
most dramatic change occurred at the normal-to-in situ
carcinoma transition. This change can be an important
marker for an early diagnosis. In another study, several
genes regulated by estrogen or tamoxifen were identified
in an estrogen-dependent breast cancer cell line. One of
them was studied closer. It appeared to play a significant
role in estrogen-promoted cell growth [42].
Gene profiles – microarrays
The DNA microarray analysis is used to identify profiles of
expressed genes in a given tissue and time. Thousands of
known cDNA sequences or oligonucleotides are
imprinted on a solid support, sometimes called a chip
(e.g., a microscope slide or a nylon membrane), using
application robots. Typically, individual spots are 100–
300 micrometers in size and are spaced about the same
distance apart [43]. More than 30,000 sequences can be
fitted on the surface of a chip. These sequences serve as
probes. Alternatively, the probes are synthesized in situ
(60-mers) [44]. By hybridization, test (target) sequences
(cDNAs or cRNAs) are bound to the cognate probes. The
basic approach is the comparison of degree of hybridiza-
tion in the control and test preparation. There are two
basic techniques for the detection of hybridization. The
control and test preparations are placed on a single chip,
or, separately, on two chips.Reproductive Biology and Endocrinology 2004, 2:68 http://www.rbej.com/content/2/1/68
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In the single chip technique [18], mRNAs from the con-
trol and test cells/tissues are separately reverse transcribed.
During the transcription processes two different
fluorescent dyes (e.g., Cy3 – green, Cy5 – red) are incor-
porated into the control and test cDNAs, respectively. The
labeled molecules are mixed and hybridized to the cDNA
array. There is a competition for each probe on the chip
between the control and test mRNAs. The test cDNAs are
selectively bound to some probes, the control cDNAs may
be bound to other probes. With use of fluorescence scan-
ning it is possible to distinguish the hybrids with control
sequences (exhibiting, e.g., green fluorescence) from the
hybrids with test sequences (e. g., red) [45]. Alternatively,
the dyes may be reversed, and the control and test cDNAs
may be labeled with the red and green dye, respectively.
The hybrids that arise when the control and test cDNA
occur in equal amounts may show a yellow fluorescence.
The black spots indicate no hybridization (Fig. 5). One of
the commercial companies utilizing this approach is Agi-
lent http://www.agilent.com/chem.
Flow-sheet of SAGE Figure 4
Flow-sheet of SAGE. mRNAs are captured on oligo(dT) magnetic beads (open ovals). Double stranded cDNAs are synthe-
sized. They are digested with Nla III. The product is divided into two halves. These are ligated to 40 bp adapters AR and BR, 
respectively. Both adapters contain a sequence R that is a recognition site for the restriction enzyme BsmFI. This cuts a 14 bp 
sequence 3' of the site, forming a 10 bp tag. After cleavage with BsmFI, the tags are ligated to form a product containing a ditag 
(the points of ligation are denoted by filled circles). This is amplified using primers complementary to A and B. The AR and BR 
adapters are cut away with Nla III to release a ditag. These are ligated to form concatemers containing multiple ditags. The con-
catemers are cloned and sequenced.
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Using a variant of the method [46,47], certain groups of
activated genes could be defined as predictors of the
clinical outcome of breast cancer. Up to 5000 genes were
tested for up-regulation (red) or down-regulation (green)
in up to 100 patients with various degrees of disease pro-
gression. Correlations of disease grades with gene expres-
sion profiles were established, and a strategy was provided
to select patients who would benefit from adjuvant
therapy.
In the two-chip technique, mRNAs of the test and control
tissues/cells is reverse transcribed into a double-stranded
cDNA from which a cRNA is prepared. In the course of the
cRNA synthesis biotin molecules are incorporated [48].
The control and test cRNAs are separately hybridized to
two identical chips. The binding is detected by staining
with a fluorescent dye coupled to streptavidin. Signal
intensities are used to calculate the relative cRNA abun-
dance for the genes represented on the array. For compar-
isons of the intensities on both chips advanced computer
programs have to be used. A combination of single-chip
and two-chip techniques was applied in a study [51]
where two chips and two fluorescent dyes were used.
Commercial systems are available from several sources.
For example, Affymetrix (GeneChip) [http://www.affyme
trix.com] produce chips by a photolithographic method
in which thousands of different oligonucleide probes are
synthesized in situ on the chip [49]. A compact technique
has been introduced by the Febit company [50]. In a sin-
gle benchtop instrument called Geniom a light-activated
oligonucleotide microarray synthesis takes place, as well
as addition of biotin-labeled cRNA sample, hybridization
and fluorescence detection after incubation with streptavi-
din-phycoerythrin [50]. Other systems for microarray pro-
duction, target preparation, hybridization and result
Model of a microarray Figure 5
Model of a microarray. In a single-chip technique reverse transcription from mRNAs to cDNAs is separately carried out for 
the test and control cell preparations. During the transcription one of the fluorescent dyes (e.g., Cy3 – green and Cy5 – red) 
are incorporated into the cDNAs of each preparation. A mixture of these two preparations is then hybridised to the corre-
sponding gene-representing sequences on a chip. The activated genes of the control sample exhibit green color, those of the 
test sample provide red spots, equally bound cDNAs can be visualized by yellow spots, no hybridization remains black.
Red
Green
Yellow
Black - no 
hybridizationReproductive Biology and Endocrinology 2004, 2:68 http://www.rbej.com/content/2/1/68
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evaluation are offered by Amersham Biosciences http://
www.amershambiosciences.com and Clondiag Chip
Technologies http://www.clondiac.com.
As a rule, more than one gene is activated, and a spectrum
of genes is discovered either occurring sporadically or in
clusters [49]. For example, when a diseased tissue was
compared with a healthy one, an expression profile, a dis-
ease fingerprint, was identified [49]. In the case of breast
tumors, a molecular portrait of each tumor was obtained
[52], or, molecular profiling (a set of gene clusters) pro-
vided predictions of responses to adjuvant treatment
[46,53]. Gene activation in breast cancer cells in the pres-
ence of E2 included, apart from the known estrogen-
responsive genes, a series of novel genes expressing
growth factors and components of the cell cycle, adhesion
molecules, enzymes, signaling molecules and transcrip-
tion factors [48]. Gene expression patterns of breast carci-
nomas allowed to distinguish tumor subclasses [54]. E2
caused up-regulation of 250 genes in vascular endothelial
cells that could be prevented by an inhibitor [55]. In an
experimental encephalomyelitis a markedly enhanced
gene activation by E2 was noted [56].
Sometimes a technically easier macroarray is used, e.g., on
a 96-well plate [57]. Obviously, the choice of gene
sequences to be used as probes must be very selective in
this case. This approach has been adopted by the SuperAr-
ray Bioscience Corporation http://www.superarray.com
offering selected profiles of genes in the macroarray for-
mat for various areas (e.g., cancer, cell cycle, cytokine and
inflammatory response, etc.).
Quite often the gene identification obtained by an array is
confirmed by other methods such as Northern blot analy-
sis [58], or real-time PCR [43,58][http://www.superar
ray.com]. A negative identification can be achieved by the
use of siRNA (small interfering RNA – SuperArray Corp.).
siRNAs are short RNA duplexes between 15 to 21 nucle-
otides in length. Once transfected into cells, a siRNA tar-
gets the mRNA containing an identical sequence and
degrades it in a catalytic manner. The degraded message is
no longer functional in translation (the biosynthesis of
protein) and thus in the expression of the corresponding
gene. SuperArray Corp. provides a line of validated popu-
lations of siRNAs in the form of SureSilencing siRNA kits.
Conclusions
The methods described above can suit two purposes. The
single-gene methods can detect and identify new, previ-
ously unknown, genes, whereas microarrays can handle a
great number of known genes to establish profiles of their
expression.
SAGE seems to have advantages over hybridization-based
methods for the studies of gene expression, such as differ-
ential display and subtractive hybridization. SAGE is
superior to the EST approach in providing high efficiency
in identifying the genes that are expressed at low levels
and that represent a majority of genes in the human
genome [36].
Microarray techniques usually detect activation of a mul-
titude of genes – a gene profile – that differs from the pro-
file in control tissues/cells and thus – in medicine – may
have a diagnostic and/or prognostic value. However, the
microarray techniques usually require commercially pro-
duced chips as well as specialized equipment and
advanced, powerful, computing facilities. Thus they are
hardly affordable for small or medium-size laboratories
unless they have substantial financial resources.
A big question at another level remains so far unanswered:
which is the biological "chain of commands" in a given
tissue and time resulting in the activation of genes ena-
bling the biosynthesis of cornerstones for gene activation,
such as ligands (e.g., E2), receptors (e.g., ER) and other
transcription factors, the entire machinery leading to gene
activation and expression.
References
1. Cekan SZ: Quantitative analysis of steroid hormone receptors
and their messenger ribonucleic acids. J Lab Clin Med 1994,
124:606-622.
2. Stavreus-Evers A, Cekan SZ: Quantitative measurements of
steroid receptors and their messenger ribonucleic acids with
a special emphasis on polymerase chain reaction. J Lab Clin
Med 2001, 137:383-397.
3. Cekan SZ: Genes and transcription factors, including nuclear
receptors: methods of studying their interactions. J Lab Clin
Med 2002, 140:215-227.
4. White RE, Darkow DJ, Lang JL: Estrogen relaxes coronary arter-
ies by opening BKCa channels through a cGMP-dependent
mechanism. Circ Res 1995, 77:936-942.
5. Pines A, Averbuch M, Fisman EZ, Rosano GMC: The acute effects
of sublingual 17 beta-estradiol on the cardiovascular system.
Maturitas 1999, 33:81-85.
6. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J,
Chambon P, Bayard F, Arnal JF: Estradiol alters nitric oxide pro-
duction in the mouse aorta through the alpha-, but not beta-
, estrogen receptor. Circ Res 2002, 8:413-419.
7. Gooren LJ, Toorians AW: Significance of oestrogens in male
(patho)physiology. Ann Endocrinol (Paris) 2003, 64:126-135.
8. Mack WJ, Hameed AB, Xiang M, Roy S, Slater CC, Stanczyk FZ, Lobo
RA, Liu CR, Liu CH, Hodis HN: Does elevated body mass modify
the influence of postmenopausal estrogen replacement on
atherosclerosis progression: results from the estrogen in the
prevention of atherosclerosis trial.  Atherosclerosis 2003,
168:91-98.
9. Thijs A, van Baal WM, van der Mooren MJ, Kenemans P, Dräger AM,
Huijgens PC, Stehouwer CDA: Effects of hormone replacement
therapy on blood platelets. Eur J Clin Invest 2002, 32:613-618.
10. Pereda CA, Hannon RA, Naylor KE, Eastell R: The impact of sub-
cutaneous oestradiol implants on biochemical markers of
bone and bone mineral density in postmenopausal women.
BJOG 2002, 109:812-820.
11. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M: Ultralow-
dose micronized 17 beta-estradiol and bone density and
bone metabolism in older women: a randomised controlled
trial. J Amer med Assoc 2003, 290:1042-1048.Reproductive Biology and Endocrinology 2004, 2:68 http://www.rbej.com/content/2/1/68
Page 10 of 11
(page number not for citation purposes)
12. Vashisht A, Studd JW: Five-year changes in bone density and
their relationship to plasma estradiol and pre-treatment
bone density, in an older population of postmenopausal
women using long-term estradiol implants. Gynecol Endocrinol
2003, 17:463-470.
13. Coser KR, Chesnes J, Hur J, Ray S, Isselbacher KJ, Shioda T: Global
analysis of ligand sensitivity of estrogen inducible and sup-
pressible genes in MCF7/BUS breast cancer cells by DNA
microarray. Proc Natl Acad Sci USA 2003, 100:13994-13999.
14. Kelly MJ, Wagner EJ, Ronnekleiv OK: Rapid effects of estrogen on
G protein-coupled receptor activation of potassium chan-
nels in the central nervous system (CNS). J Steroid Biochem Mol
Biol 2002, 83:187-193.
15. Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB,
Rowan JP: Efficacy and local tolerance of a low-dose, 7-day
matrix estradiol transdermal system in the treatment of
menopausal vasomotor symptoms.  Obstet Gynecol 1996,
88:587-592.
16. Marin-Castano ME, Elliot SJ, Potier M, Karl M, Striker LJ, Streiker GE,
Csaky KG, Cousins SW: Regulations of estrogen receptors and
MMP-2 expression by estrogens in human retinal pigment
epithelium. Invest Ophtalmol Visual Sci 2003, 44:50-59.
17. Post MS, Christelle M, Thomassen LG, van der Mooren MJ, van Baal
WM, Rosing J, Stehouwer CD: Effect of oral and transdermal
estrogen replacement therapy on hemostatic variables asso-
ciated with venous thrombosis: a randomised, placebo-con-
trolled study in postmenopausal women.  Arterioscler Thromb
Vasc Biol 2003, 23:1116-1121.
18. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J:
Molecular Cell Biology 4th edition. New York: Media Connected; 1999. 
19. Welsh J, Chada K, Dalal SS, Cheng R, Ralph D, McClelland M: Arbi-
trarily primed PCR fingerprinting of RNA. Nuclelc Acids Res
1992, 20:4965-4970.
20. Liang P, Pardee AB: Differential display of eukaryotic messen-
ger RNA by means of the polymerase chain reaction. Science
1992, 257:967-971.
21. Mou L, Miller H, Li J, Wang E, Chalifour L: Improvements to the
differential display method for gene analysis. Biochem Biophys
Res Commun 1994, 199:564-569.
22. Sompayrac L, Jane S, Burn TC, Tenen DG, Danna KJ: Overcoming
limitations of the mRNA differential display technique.
Nuclelc Acids Res 1995, 23:4738-4739.
23. Lee SW, Tomasetto C, Sager R: Positive selection of candidate
tumor-suppressor genes by subtractive hybridisation.  Proc
Natl Acad Sci USA 1991, 88:2825-2829.
24. Yancopoulos GD, Oltz EM, Rathbun G, Berman JE, Smith RK, Lans-
ford RD, Rothman P, Okada A, Lee G, Morrow M, Kaplan K, Prockop
S, Alt FW: Isolation of coordinately regulated genes that are
expressed in discrete stages of B-cell development. Proc Natl
Acad Sci USA 1990, 87:5759-5763.
25. Suzuki M, Nishiara M: Granulin precursor gene: a sex steroid-
inducible gene involved in sexual differentiation of the rat
brain. Molec Genetics Metab 2002, 75:31-37.
26. Diatchenko L, Lau Y-FC, Campbell AP, Chenchik A, Moqadam F,
Huang B, Lukyanov K, Gurskaya N, Sverdlov ED, Siebert PD: Sup-
pression subtractive hybridisation: a method for generating
differentially regulated or tissue-specific cDNA probes and
libraries. Proc Natl Acad Sci USA 1996, 93:6025-6030.
27. Gurskaya NG, Diatchenko L, Chenchik A, Siebert PD, Khaspekov GL,
Lukyanov KA, Vagner LL, Ermolaeva OD, Lukyanov SA, Sverdlov ED:
Equalizing cDNA subtraction based on selective suppression
of polymerase chain reaction: cloning of Jurkat cell tran-
scripts induced by phytohemaglutinin and phorbol 12-myr-
istate 13-acetate. Anal Biochem 1996, 240:90-97.
28. Ginger MR, Gonzalez-Rimbau MF, Gay JP, Rosen JM: Persistent
changes in gene expression induced by estrogen and proges-
terone in the rat mammary gland.  Molec Endocrinol 2001,
15:1993-2009.
29. Lisitsyn N, Lisitsyn N, Wigler M: Cloning the differences between
two complex genomes. Science 1993, 259:946-951.
30. Hubank M, Schatz DG: Identifying differences in mRNA expres-
sion by representational difference analysis of cDNA. Nuclelc
Acids Res 1994, 22:5640-5648.
31. Adams MD, Kelley JM, Gocayne JD, Dubnick M, Polymeropoulos MH,
X i a o  H ,  M e r r i l l  C R ,  W u  A ,  O l d e  B ,  M o r e n o  R F ,  K a r l a v a g e  A R ,
McCombie WR, Venter JC: Complementary DNA sequencing:
expressed sequence tags and human genome project. Science
1991, 252:1651-1656.
32. Adams MD, Dubnick M, Kerlavage AR, Moreno R, Kelley JM, Utter-
back TR, Nagle JW, Fields C, Venter JC: Sequence identification
of 2,375 human brain genes. Nature 1992, 355:632-634.
33. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW: Serial analysis
of gene expression. Science 1995, 270:484-487.
34. Chen J, Sun M, Lee S, Zhou G, Rowley JD, Wang SM: Identifying
novel transcripts and novel genes in the human genome
using novel SAGE tags.  Proc Natl Acad Sc USAi 2002,
99:12257-12262.
35. Boheler KR, Stern MD: The new role of SAGE in gene
discovery. Trends Biotechnol 2003, 21:55-57.
36. Wang SM: Response: the new role of SAGE in gene discovery.
Trends Biotechnol 2003, 21:57-58.
37. Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, Riggins
G, Polyak K: A SAGE (serial analysis of gene expression) view
of breast tumor progression. Cancer Res 2001, 61:5697-5702.
38. Chen J-J, Rowley JD, Wang SM: Generation of longer cDNA frag-
ments from serial analysis of gene expression tags for gene
identification. Proc Natl Acad Sci USA 2000, 97:349-353.
39. Lee S, Clark T, Chen J, Zhou G, Scott R, Rowley JD, Wang SM: Cor-
rect identification of genes from serial analysis of gene
expression tag sequences. Genomics 2002, 79:598-602.
40. Chen J, Lee S, Zhou G, Wang SM: High-troughput GLGI proce-
dure for converting a large number of serial analysis of gene
expression tag sequences into 3' complementary DNAs.
Genes Chromosomes Cancer 2002, 33:252-261.
41. Saha S, Sparks AB, Rago C, Akmaev V, Wang CJ, Vogelstein B, Kinzler
KW, Velculescu VE: Using the transcriptome to annotate the
genome. Nature Biotechnol 2002, 19:508-512.
42. Seth P, Krop I, Porter D, Polyak K: Novel estrogen and tamoxifen
induced genes identified by SAGE (serial analysis of gene
expression). Oncogene 2002, 21:836-843.
43. Schulze A, Downward J: Navigating gene expression using
microarrays – a technology review.  Nature Cell Biol 2001,
3:E190-E195.
44. Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW,
Lefkowitz SM, Ziman M, Schelter JM, Meyer MR, Kobayashi S, Davis
C, Dai H, He YD, Stephaniants SB, Cavet G, Walker WL, West A,
Coffey E, Shoemaker DD, Stoughton R, Blanchard AP, Friend SH, Lin-
sley PS: Expression profiling using microarrays fabricated by
an ink-jet oligonucleotide synthetizer. Nature Biotechnol 2001,
19:342-347.
45. Loning PE, Sorlie T, Perou CM, Brown PO, Botstein D, Borresen-Dale
A-L:  Microarrays in primary breast cancer – lessons from
chemotherapy studies. Endocrine-Related Cancer 2001, 8:259-263.
46. Van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M,
Peterse HL, van der Kooy , Marton MJ, Witteveen AT, Schreiber GJ,
Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene
expression profiling predicts clinical outcome of breast
cancer. Nature 2002, 415:530-536.
47. Van de Vijver MJ, He YD, van t' Veer LJ, Dai H, Hart AAM, Voskuil
DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M,
Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink
H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expres-
sion signature as a predictor of survival in breast cancer. N
Engl J Med 2002, 347:1999-2009.
48. Soulez M, Parker MG: Identification of novel oestrogen recep-
tor target genes in human ZR75-1 breast cancer cells by
expression profiling. J Mol Endocrinol 2001, 27:259-274.
49. Kurella M, Hsiao L-L, Yoshida T, Randall JD, Chow G, Sarang SS,
Jensen RV, Gullans SR: DNA microarray analysis of complex
biologic processes. J Am Soc Nephrol 2001, 12:1072-1078.
50. Baum M, Bielau S, Rittner N, Schmid K, Eggelbusch K, Dahms M,
Schlauersbach A, Tahedl H, Beier M, Güimil R, Scheffler M, Hermann
C, Funk J-M, Wixmerten A, Rebscher H, Hönig M, Andreae C, Büch-
ner D, Moshel E, Glathe A, Jäger E, Thom M, Greil A, Bestvater F,
Obermeier F, Burgmeier J, Thome K, Weichert S, Hein S, Binnewies
T, Foitzik V, Müller M Stähler CF, Stähler PF: Validation of a novel,
fully integrated and flexible microarray benchtop facility for
gene expression profiling. Nucl Acids Res 2003, 31:e151.
51. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW: Paral-
lel human genome analysis: microarray-based expression
monitoring of 1000 genes.  P r o c  N a t l  A c a d  S c i  U S A  1996,
93:10614-10619.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Reproductive Biology and Endocrinology 2004, 2:68 http://www.rbej.com/content/2/1/68
Page 11 of 11
(page number not for citation purposes)
52. Perou CM, Sorlie T, Eisen MB, Van de Rijn M, Jeffrey SS, Rees CA, Pol-
lack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A,
Williams C, Zhu SX, Lonning PE, Borresen-Dale A-L, Brown PO, Bot-
stein D: Molecular portraits of human breast tumours. Nature
2000, 406:747-752.
53. Caldas C, Aparicio SAJ: The molecular outlook.  Nature 2002,
415:484-485.
54. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie
T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC,
Brown PO, Botstein D, Lonning PE, Borresen-Dale A-L: Gene
expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA 2001,
19:10869-10874.
55. Pedram A, Razandi M, Aitkenhead M, Hughes ccw, Levin ER: Integra-
tion of the non-genomic and genomic actions of estrogen. J
Biol Chem 2002, 277:50768-50775.
56. Matejuk A, Dwyer J, Zamora A, Vandenbark AA, Offner H: Evalua-
tion of the effects of 17 beta-estradiol (17-beta-E2) on gene
expression in experimental autoimmune encephalomyelitis
using DNA microarray. Endocrinology 2002, 143:313-319.
57. Krebs KC, Brzoza KL, Lan Q: Use of subtracted libraries and
macroarray to isolate developmentally specific genes from
the mosquito, Aedes aegypti.  Insect Biochem Molec Biol 2002,
32:1757-1767.
58. Bustin SA: Absolute quantification of mRNA using real-time
reverse transcription polymerase chain reaction assays. J Mol
Endocrinol 2000, 25:169-193.